Norman Wang, MD
Neurology · Phoenix, AZNPI 1790713907
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 180 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,578 and has fallen 59.9% since, to $633 in 2025.
Across 180 payments — averaging $31.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$1K
- Eisai Inc.$779
- SK Life Science, Inc.$752
- Sunovion Pharmaceuticals Inc.$469
- Neuropace, Inc.$447
- AbbVie$432
- plus $2K from 16 others
Across 25 payments — averaging $5458.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$89K
- SK Life Science, Inc.$32K
- Biogen$8K
- UCB SA$5K
- Sunovion Pharmaceuticals Inc.$3K
What the payments were for
- Food & beverage$5,632100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 27 | $1,197 |
| Eisai Inc. | 31 | $779 |
| SK Life Science, Inc. | 13 | $752 |
| Sunovion Pharmaceuticals Inc. | 20 | $469 |
| Neuropace, Inc. | 10 | $447 |
| AbbVie(2 entities) | 22 | $432 |
| UCB, Inc. | 25 | $302 |
| Jazz Pharmaceuticals Inc. | 4 | $291 |
| AstraZeneca | 7 | $214 |
| Neurelis, Inc. | 3 | $189 |
| Greenwich Biosciences, Inc. | 4 | $125 |
| Medtronic | 1 | $109 |
| Monteris Medical Corporation | 1 | $103 |
| Neurocrine Biosciences, Inc. | 2 | $46 |
| Lundbeck LLC | 2 | $40 |
| Zogenix Inc. | 2 | $31 |
| Relievant Medsystems, Inc. | 1 | $22 |
| Amgen | 1 | $19 |
| Merz North America, Inc. | 1 | $19 |
| Aquestive Therapeutics, Inc. | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$308
- RNS System$210
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$132
- Epidiolex$122
- Fintepla$122
- ULTOMIRIS$121
- XCOPRI$117
- SenSight$109
- VALTOCO$107
- Neuroblate$103
How this compares
$5,632 in reported general payments places this provider in the 60th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 18 | $770 |
| Lamotrigine | 18 | $504 |
Paid to pharmacies, not to this prescriber.
Other neurology in Phoenix
- Barry HendinPhoenix$2.3M
- Maria OspinaPhoenix$2.1M
- Suraj MuleyPhoenix$1.7M
- Eric ErossPhoenix$778K
- Steve ChungPhoenix$685K
- Marwan SabbaghPhoenix$603K
- Kerry KnievelPhoenix$509K
- Lori TravisPhoenix$406K
- Jeffrey GittPhoenix$275K
- Todd SchwedtPhoenix$273K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.